key: cord-0746588-djlbyaez
authors: Li, Jiarui; Du, Pengcheng; Yang, Lijiang; Zhang, Ju; Song, Chuan; Chen, Danying; Song, Yangzi; Ding, Nan; Hua, Mingxi; Han, Kai; Song, Rui; Xie, Wen; Chen, Zhihai; Wang, Xianbo; Liu, Jingyuan; Xu, Yanli; Gao, Guiju; Wang, Qi; Pu, Lin; Di, Lin; Li, Jie; Yue, Jinglin; Han, Junyan; Zhao, Xuesen; Yan, Yonghong; Yu, Fengting; Wu, Angela R.; Zhang, Fujie; Gao, Yi Qin; Huang, Yanyi; Wang, Jianbin; Zeng, Hui; Chen, Chen
title: Two-step fitness selection for intra-host variations in SARS-CoV-2
date: 2021-12-16
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.110205
sha: 1fc008dcdc46b6e165ee8a71fb9463f4f9e99c80
doc_id: 746588
cord_uid: djlbyaez

Spontaneous mutations introduce uncertainty into COVID-19 control procedures and vaccine development. Here, we perform spatio-temporal analysis on intra-host single-nucleotide variations (iSNVs) in 402 clinical samples from 170 patients, which reveals an increase in genetic diversity over time post-symptoms onset within individual patients. Nonsynonymous mutations are over-represented in the pool of iSNVs, but underrepresent at the single nucleotide polymorphism (SNP) level, suggesting a two-step fitness selection process: a large number of nonsynonymous substitutions are generated within the host (positive selection), and these substitutions tend to be unfixed as SNPs in population (negative selection). Dynamic iSNVs changes in subpopulations of different gender, age, illness severity and viral shedding time displayed a varied fitness selection process among populations. Taken together, our study highlights iSNVs provide a mutational pool shaping the virus rapid global evolution.

` nonsynonymous sites in predicted epitope regions and the time of symptoms onset 245 revealed that the number of nonsynonymous sites in the S gene increased as the 246 disease progressed ( Figure S2D) . We measured all mutational types for all iSNVs, and the top five iSNV mutation 272 types were ranked as follows (most to least common): U-to-C, C-to-U, G-to-U, A-to-273 G, and G-to-A ( Figure 3A) ; four of them might be introduced by APOBEC and 274 ADAR. Unlike the A-to-I RNA editing signal in the human transcriptome, we did not 275 observe obvious depletion of G bases in position -1 ( Figure S3A) . To evaluate the 276 dynamic change of RNA-editing levels along with disease progress, we calculated the 277 correlations between the minor allele frequencies of iSNVs and the time after 278 symptoms onset. Consistently, the minor allele frequencies of C-to-U and G-to-A 279 mutations due to APOBEC-mediated RNA editing were slightly increased in vivo. In 280 contrast, the frequencies of other mutational types, including ADAR-mediated RNA 281 editing in vivo, did not increase with the duration of infection. This identification was 282 consistent with previous studies which found that coronavirus infection induced 283 APOBEC activity, but not ADAR activity. We next compared the mutational types 284

and their levels of accumulation for both nonsynonymous and synonymous mutations. groups. Therefore, we evaluated the influence of host effects on viral mutation, and 297 measured dynamic changes in the number of iSNVs within groups of patients based 298 on gender, age, illness severity, and viral shedding time (Table 1) . Each sample was 299 J o u r n a l P r e -p r o o f ` recalibrated based on symptoms onset date. Increased genetic diversity of iSNVs was 300 observed in all groups ( Figure 4A) , suggesting that accumulation of iSNVs occurred 301 in all populations rather than a specific population. We also observed different slopes 302

and initial values in the fitness linear model between iSNVs number and time post-303 symptoms onset in these patient groups ( Figure 4B) . A higher accumulation rate was 304 observed in middle-aged patients (15-65 year) compared to elderly patients (p-value 305 =0.037, ANOVA test), especially in patients whose viral shedding time was more 306 than 6 weeks (p-value =0.041, ANOVA test, Figure S4A ). We also observed a 307 significant increase in nonsynonymous sites in mid-age compare to elderly patients 308 (p-value =0.035, ANOVA test), while the synonymous accumulation rate did not 309 differ among different age groups ( Figure S4B , Figure S4C ). The different iSNV 310 accumulation rate suggests the presence of a different fitness selection process during 311 the initial infection stage and subsequent infection stages after symptoms onset 312 ( Figure 4A) . 313

To further investigate specific mutations that could be influenced by host effects we 314 compared the proportions of patients with and without recurrently mutated sites 315 ( Figure 4C ). We constructed a matrix of patients with/without iSNVs based on 52 316 iSNV sites shared by more than six patients among a group of 170 patients. These 317 patients were categorized into four independent classes: gender, age, illness severity 318 and viral shedding time (Table 1) . Each iSNV site was subjected to an independent 319

Fisher's exact test. Patients with severe disease, elderly patients, patients with long 320 viral shedding time, and male patients preferentially showed significant enrichment in 321 4, 5, 4, and 8 iSNVs, respectively, compared with patients with mild/moderate 322 disease, children/middle-aged patients, patients with short viral shedding time (<6 323 weeks), and female patients ( Figure 4C ). These iSNVs were distributed in ORF1ab, 324 S, N, ORF6 and ORF8. Among the 52 recurrent iSNV sites, we identified 27 sites that 325 preferentially occurred in patients with severe disease, of which 12 overlapped with 326 previously reported hfSNP sites in the public database 2019nCoVR. In contrast, the 327 J o u r n a l P r e -p r o o f ` 25 iSNVs that preferentially occurred in patients with moderate disease did not 328 overlap with hfSNPs sites ( Figure 4D , p-value < 0.001, Fisher's exact test). This 329 enrichment of hfSNPs sites was not observed in any other categories that were 330 stratified based on gender, age, and viral shedding time, indicating a non-stochastic 331 process. 332

To identify the mutations fixed from iSNVs to SNPs, we compared the genomic sites 334 of iSNVs and SNPs in the 2019nCoVR database Zhao et al., 335 2020a). Among 7,037 iSNVs, 15.59% of iSNVs had already been identified as SNPs 336 before our observation period (May, 2020), and 11.28% of iSNVs were fixed from 337

May, 2020 to December, 2020, while the remaining iSNVs (73.13%) were not fixed 338 as SNPs ( Figure 5A) . Nonsynonymous iSNVs displayed a lower fixation rate in 339 comparison with that of synonymous iSNVs (20.92% vs. 41.12%, p-value < 0.001, 340

Fisher's exact test; Figure 5B ). This finding is supported by a model in which 341 nonsynonymous iSNVs occur at a high frequency within an individual due to positive 342 selection or incomplete purifying selection, but are less likely to become fixed in the 343 population due to purifying selection. Next, we performed Fisher's exact test to 344 compare the proportion of fixed mutations in each gene, and S and ORF1ab were 345 found to have lower fixation rates (21.04% and 20.56%, respectively, Figure 5C ) at 346 nonsynonymous and synonymous sites ( Figure S5A) . Consistently, the 347 nonsynonymous-to-synonymous ratios of iSNVs in ORF1ab, N and S (excluding 348 D614G) were greater than those estimated for the identified SNPs, consistent with 349 uneven purifying selection of these genes ( Figure 5D ). With disease progression, 350 iSNV fixation rates in nonsynonymous and synonymous sites were stable in the 351 population ( Figure 5E, Figure S5B ), indicating a process of similar purifying 352 selection as the disease progressed. We also observed that mutation might have 353 occurred in iSNVs before they were fixed as SNPs. For example, accumulation of 354 C7051T alleles was observed in our study before May, whereas the first C7051T SNP 355 J o u r n a l P r e -p r o o f ` was not reported until June, 2020 ( Figure 5F ). Although sampling bias might have 356 also limited our observation of SNPs in the early stages of the epidemic period, our 357 observation of mutations at the iSNV level might have increased our detection 358 sensitivity for mutations before they were fixed. These results indicate that iSNVs 359 provide a complementary resource of genetic information to illuminate the 360 evolutionary history of SARS-CoV-2. 361

The S protein drives cellular binding and entry through receptors and acts as a major 363 determinant of the host range, cell type, tissue tropism, and pathogenesis of 364 coronaviruses (Li, 2013) . Therefore, we analysed 21 nonsynonymous sites of 606 365 iSNV sites identified in the coding region of the S protein, which caused 20 amino 366 acids changes: (1) nine were detected outside the receptor-binding domain (RBD) 367 region in more than six individuals, including substitution of two amino acids change 368 in three linked iSNVs (R246E and S247N caused by A22298G, G22299A and 369 G22302A, Figure 6A ) ; (2) eleven resided within the RBD or S1/S2 cleavage sites in 370 more than two individuals, including seven iSNVs located in the receptor-binding 371 motif (RBM). Since few of these mutations had been reported in SARS-CoV-2, we 372 compared the mutation sites of seven iSNVs in the RBM of SARS-CoV-2 with the 373 consensus sequences of SARS-CoV-2-like coronaviruses in other animals (bat and 374 pangolin) to explore their potential molecular functions. All of these sites were 375 heterogeneous, suggesting that mutations in these protein sites may not be random 376 mutations ( Figure 6A ). In addition, patients with these mutations had no contact 377 history except for two patients with the G485V mutation (Table S4) . No iSNVs had 378 emerged in patients at the first time point of genome sequencing ( Figure S6A , Table  379 S4), and no evidence indicated that these iSNVs were linked in the genome. Thus, 380

these results indicate that iSNVs in the RBD seem to be generated by independent 381 viral evolution. 382 J o u r n a l P r e -p r o o f ` To elucidate the effects of these mutations at the molecular level, we first used the 383 SARS-CoV-2 pseudovirus infection assay in HEK293T cells to assess the viral entry 384 efficacy of 20 of the 22 S protein mutants, excluding S50L and M731V, which we 385 failed to obtain in the mutation assay. Compared with the reference strain, 18 of the 386 20 tested mutants displayed a decreased (fold change <0.25, p-value < 0.05, t-test) or 387 comparable (fold change <4 or >0.25) viral entry efficacy; only mutants R685G and 388 D614G exhibited a similar level of increased viral entry efficacy ( Figure 6B , Table  389 S5, fold change >4, p-value < 0.05, t-test). Since the L518V mutation is far away from 390 the binding interface between the S protein and hACE2/CB6, and four mutants 391 (N422K, E471K, G485V and Y505C) displayed a significant decrease (fold change 392 <0.25) in viral entry efficacy, the other five RBD mutants (V407L, L452Q, V483F, 393

Q493H and Q498H) were tested for sensitivity to CB6 (Table S6) . Wild-type (WT) 394

and D614G viruses were included as controls. Modest differences between these RBD 395 variants and the reference strain (4-fold) were observed with regard to susceptibility 396 to CB6 (Table S5) . Some variants, including V483F, Q493H and Q498H, were even 397 more sensitive than the reference strain to CB6, which indicated that CB6 antibodies 398 could block viral entry despite the RBD mutations. 399

Next, we focused on mutations within the RBM by simulating the binding of the 400 corresponding mutants to human angiotensin-converting enzyme 2 (hACE2) (Wang et was mutated to change its uncharged N side chain to a positively charged K, 412 producing the N422K mutant. Consequently, a much stronger hydrogen bond (salt 413 bridge) was formed between K422 and E406. In addition, strong repulsion between 414 K422 and R403, as well as attraction between K422 and Y453, caused breakage of the 415 hydrogen bonds between Y505 and E37, as well as those between Y453 and H34. As 416 a result, both the number of hydrogen bonds and the contact area formed between the 417 mutant RBDs and hACE2 were reduced ( Figure 6D ). Regarding the G485V mutation, 418 V has a relatively bulky side chain compared to G; in order to reposition this bulky 419 side chain, the G485V mutation led to the expulsion of F486 from the hydrophobic 420 pocket formed by residues including F28, L79, M82 and Y83 of hACE2. As a result, 421 both the contact area and the number of hydrogen bonds formed between the mutant 422 RBD and hACE2 were reduced. Importantly, the hydrogen bond formed between 423 Y505 of the S protein and E37 of hACE2, which is important for binding, was lost 424 ( Figure 6E ). As a possible consequence, the binding of mutants N422K/G485V to 425 hACE2 was weakened. Binding free energy calculations using the MM/GBSA 426 method also indicated weakened binding of N422K/G485 to hACE2 ( Figure 6C ). 427

Changes in hydrogen bonding and contact area were also investigated for other 428 mutants ( Figure S6B ). Most of the mutants with iSNVs displayed decreased viral 429 entry ability due to fewer hydrogen bonds and/or reduced contact area between 430 mutant RBDs and hACE2. We also analysed simulation results for complexes 431 between mutant RBDs and the CB6 antibody ( Figure S6C ). Most of the mutants 432 exhibited greatly reduced contact area compared with that of the WT sequence. The ongoing SARS-CoV-2 pandemic is of worldwide concern. SARS-CoV-2 440 mutations arise naturally as the virus replicates, and the resulting SNPs may impact Limitation of this study 519

Our study described the dynamic change of iSNVs in patients. However, limited by 520 the number of patients, we did not observe a significant difference in distinct patient 521 groups. The relationship between immune pressure and iSNV dynamics will be an 522 interesting and important future study. Figure S1 and Table S2 . causing A to G and T to C) and APOBEC targets (C to U, causing C to T and G to A) 560 against time post-symptoms onset of patients. See also Figure S3 . Figure S6 , Table S4 ,Table S5 and Table S6 . transcriptase, after which it was incubated at 42C for 15 min to fill the gaps, 720 followed by 70C for 15 min to inactivate SuperScript II reverse transcriptase. Next, 721 index PCR was performed by adding 4 ml 10 mM unique dual index primers and 4 ml 722 Q5 High-Fidelity 2X Master Mix, and thermal cycling was performed at 98C for 30 723 J o u r n a l P r e -p r o o f ` s, followed by 18 cycles at 98C for 20 s, 60C for 20 s, and 72C for 2 min, with a 724 final step at 72C for 5 min. The PCR product was then purified using 0.8 VAHTS 725

The meta-transcriptome libraries were further enriched using biotinylated 727 RNA/cDNA probes targeting the whole viral genome (iGeneTech, Beijing, China). 728

The library was first quantified for the N gene using quantitative PCR after a 1:200 729 dilution. Next, 816 libraries were pooled together based on qPCR results. The 

To test if the difference of observed number of iSNVs were due to false positive in 801 low viral load samples, we plot the iSNV numbers to Ct value and found that iSNV 802 richness slightly decreased with higher viral load, consistent with the previous report 803 

To determine the potential false positive result, we sequenced 95 negative control 809 samples from 31 individuals, including 40 pharyngeal swab, 15 sputum and 40 faeces. 810

We obtained 1502 reads mapped to the SARS-CoV-2 genome in median for the 811 negative control sample. All of the negative control sample did not meet the crania of 812 complete genome (consensus genome >50% and deep sequencing genome >10%) 813

( Figure S7H ). The reads mapped to the SARS-CoV-2 genome showed significant 814 difference in the negative control vs. high and low coverage samples ( Figure S7I) . 815 816

The number of iSNVs for each sample was normalised by the number of iSNVs per 818 kb, with only the region used to identify iSNVs used for calculation. The iSNV sites 819

were identified throughout the genome by removing duplicated iSNVs in each patient, 820 ensuring that iSNVs in different samples from each patient were only counted once. 821

We also applied linear regression to evaluate the correlation between iSNVs and the 822 *   A27809T  C25721T  G18089T  G23016T  G9479T  T19236A  A22298G  A29869G  A6029G  C21711T  C23643A  G12575T  G28209T  A23753G  C11931T  C14322T  C23874T  C27335T  T16254C  T8431G  C313T  A25497G  G25527A  T14950C  T28688C  A14193C  C241T  G22299A  G11083T  G22302A  T8429C  T9201C  A11201G  G25563T  G28881A  A23403G  G28883C  T28144C  A24950T C21639A 

Severe Non-severe 

Clinical Sequencing Uncovers Origins and Evolution of Lassa 1020 Virus

Case Study: Prolonged Infectious SARS-CoV

Shedding from an Asymptomatic Immunocompromised Individual with

Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable

A review of mathematical models of influenza A infections 1029 within a host or cell culture: lessons learned and challenges ahead

Quantifying Clonal and Subclonal Passenger Mutations 1031 in Cancer Evolution

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-1034 to-person transmission: a study of a family cluster

Phylogenomic analysis unravels evolution of yellow fever virus within hosts

MINERVA: A Facile Strategy for SARS-CoV-2 Whole-Genome Deep Sequencing of Clinical Samples

Coronaviridae Study Group of the International Committee on Taxonomy of

Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-1043

Particle mesh Ewald: An N⋅ log (N) method 1045 for Ewald sums in large systems

Vaccination has minimal impact on the intrahost diversity of H3N2 influenza 1048 viruses

IEDB-AR: immune epitope database-analysis resource in 1051 2019

Evidence for 1053 host-dependent RNA editing in the transcriptome of SARS-CoV-2

Extensive Positive Selection Drives the Evolution of Nonstructural Proteins in Lineage C 1056

Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent 1058 public health alert

Spread of SARS-CoV-2 in 1061 the Icelandic population

Impaired type I interferon activity and inflammatory responses 1064 in severe COVID-19 patients

The evolution of Ebola virus: 1066 Insights from the 2013-2016 epidemic

Identifying selection in the within-host evolution 1068 of influenza using viral sequence data

SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique 1070 T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene

Comparison of simple potential functions for simulating liquid water

Chronic pain after COVID-19: implications for 1074 rehabilitation

Tracking Changes in SARS-CoV-2 Spike: Evidence that 1077 D614G Increases Infectivity of the COVID-19 Virus

Evolution and Spread of Ebola Virus in Liberia

Fast gapped-read alignment with Bowtie 2

Receptor recognition and cross-species infections of SARS coronavirus

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

SARS-CoV-2 within-host diversity and transmission

ff14SB: improving the accuracy of protein side chain and backbone parameters 1099 from ff99SB

Stochastic processes constrain the within and between host evolution of influenza virus

SARS-CoV-2 spike L452R variant evades cellular immunity and increases 1104 infectivity

An Assessment of Amplicon-Sequencing Based Method for Viral 1106 Intrahost Analysis

Intra-host dynamics of Ebola virus during

Persistence and Intra-Host Genetic Evolution 1111 of Zika Virus Infection in Symptomatic Adults: A Special View in the Male Reproductive System

Spike mutation D614G alters SARS-CoV-2 fitness

Two linear epitopes on the SARS-CoV-2 spike protein that elicit 1118 neutralising antibodies in COVID-19 patients

Genomic epidemiology of superspreading events in Austria reveals 1121 mutational dynamics and transmission properties of SARS-CoV-2

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic

Numerical integration of the cartesian 1126 equations of motion of a system with constraints: molecular dynamics of n-alkanes

Mechanisms of viral mutation

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and 1133 correlates of severity

GISAID: Global initiative on sharing all influenza data -from vision 1135 to reality

Antigenic cooperation among intrahost HCV 1137 variants organized into a complex network of cross-immunoreactivity

The 1140 global landscape of SARS-CoV-2 genomes, variants, and haplotypes in 2019nCoVR

Sex differences in immune responses that underlie COVID-19 disease 1144 outcomes

On the origin and continuing evolution of SARS-CoV-2

The COVID-19 vaccine development landscape

Patterns of within-host genetic diversity in SARS-1151

CoV-2. Elife 10

Positive 1153 Selection of ORF1ab, ORF3a, and ORF8 Genes Drives the Early Evolutionary Trends of SARS-CoV

During the 2020 COVID-19 Pandemic

KaKs_Calculator 2.0: a toolkit incorporating 1156 gamma-series methods and sliding window strategies

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

A new coronavirus associated with human respiratory disease in China

Linking influenza virus evolution within and between human hosts

Within-Host Evolution of Human

Viral 1168 and host factors related to the clinical outcome of COVID-19

Computing Ka and Ks with a consideration of unequal transitional 1170 substitutions

The 2019 novel coronavirus resource

Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-1175

Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute 1178 respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering 1179 the glycan processing of angiotensin I-converting enzyme 2

A human circulating immune cell landscape in aging and COVID-19

Host-Specific Evolutionary and Transmission Dynamics Shape the Functional Diversification of 1184 Staphylococcus epidermidis in Human Skin

A Novel Coronavirus from Patients with Pneumonia in China

ORF1ab:G5942V ORF7b:L18L ORF1ab:G3072C S:G485V ORF3a:A110V ORF1ab:C6324* S:R246G 3'UTR ORF1ab:N1922D ORF8:E106* S:A694D S:S50L ORF1ab:A4104S ORF1ab:S2722S ORF1ab:V5330V ORF1ab:A3889V ORF1ab:Y4686Y ORF6:T45I S:M731V S:A771V ORF1ab:L16L ORF3a:I35M ORF3a:W45* ORF1ab:F4896L N:L139L S:R246K 5'UTR ORF1ab:L4643F ORF1ab:L3606F S:S247N ORF1ab:S2722P ORF1ab:F2979S ORF3a:Q57H N:R203K ORF1ab:T3646A S:D614G N:G204R ORF8:L84S S:P26H S:I1130L ORF1ab:L3234L ORF8:V62L N:R203R ORF1ab:S2839S ORF1ab:A5703A N:F274F ORF1ab:P4715L ORF1ab:I3731I ORF3a:G251V ORF6:K48I

` where μ represents the mutation rate per genome per replication cycle, b represents 834 the virus reproduction rate, and d represents the rate of virus decline in the population. 835We applied a generalised linear model to calculate the parameters and plotted the 836 predicted values. The SARS-CoV-2 virus reproduction and decline rates b and d were 837 not clear at the time of the study. Therefore, for comparisons of mutation rates, the 838 numbers of expected mutations with different mutation rates were calculated using the 839 virus reproduction and decline rates reported for influenza virus (Beauchemin and 840 Handel, 2011; Xue et al., 2018) . 841Simulation of the iSNV mutation position distribution was performed with the runif 842 function in the R using a uniform distribution with the number of iSNVs as 843 parameters. We then ranked the actual iSNVs and simulated positions, after which we 844 calculated the genomic distance between pairs of neighbouring mutants. The genomic 845 distance between pairs of simulated iSNVs followed the Poisson distribution. The iSNVs were annotated by Perl scripts and compared with the genomic annotation 849 file of reference genome Wuhan-Hu-1 (NC_045512.2) from the NCBI. Public SNP 850 files were downloaded from the 2019nCoVR public database (Song et (Table S10) . We also explored 869 the experimental epitope regions with the same parameters as the predicted epitopes, 870 but with two different parameters: 'Epitopes' set to 'Any' and 'Assay' set to 'B Cell 871Assays: neutralisation |biological activity'. 872 873

Pairwise phasing analysis was performed for adjacent iSNVs (distance <50 bp) as 875 previously reported . For a given pairwise iSNV, reads harbouring 876 both positions were extracted from the alignment (SAM file). Reads with both sites 877 mutated were designated as phased reads, and those with only one site mutated were 878 designated as non-phased reads. Reads with a ratio of phased to non-phased 879 reads >0.9 were selected as phased iSNVs. Moreover, the phased alternative iSNV 880 allele frequency was required to be >0.05. For phased iSNVs in a given protein 881 codon, we re-annotated the iSNVs with phased alleles. 882Despite the short distance (<50 bp) in the genome, the correlations between long-883 distance (>50 bp) pairwise iSNVs were calculated by the linear adjusted R-square of 884 variation. iSNVs were considered to be highly correlated and potentially linked if they 885were identified in at least three samples and possessed highly correlated MuAFs 886 (>0.6). adjust the mass of the heavy atom to which the hydrogen was attached so that the total 899 mass remained constant. Thus, all dynamics utilised a 4 fs time step. Long-range 900 electrostatics were treated using the particle-mesh Ewald (PME) (Darden et al., 1993 ) 901 method with default settings, and a 9 Å direct space non-bonded cutoff was used in all 902 simulations. The system was first subjected to 10,000 steps of minimisation, after 903 which it was gradually heated to 300 K under constant volume conditions in 1 ns. 904After another 5 ns of simulation using the constant isothermal-isobaric ensemble at 1 905 atm and 300 K, each system was equilibrated for an additional 10 ns. A Monte Carlo 906 barostat and a weak-coupling thermostat were used. The MD simulations were 907 performed for 300 ns with coordinates recorded every 10 ps. The same procedure was 908 followed for simulations of the CB6 antibody and the RBD complex 909 (PDB ID 7C01 and 7BWJ). Nine RBD mutants (V407L, N422K, L452Q, E471K, 910 V483F, G485V, Q493H, Q498H and Y505C) bound to either hACE2 or CB6 were 911 also simulated. Simulations of these systems were performed with the procedure 912 described above. In the analysis of simulation trajectories, hydrogen bonds were 913 defined as a geometry with a cut-off length of 3.5 Å between the two heavy atoms of 914 the hydrogen bonding donor and acceptor, and an X-H· · ·Y (X and Y represent heavy 915 atoms) angle cutoff of 135°. A hydrogen bond was counted when the distance 916 between X and Y was less than 3.5 Å and the X-H· · ·Y angle was greater than 135°. 

variants 920The codon-optimised S gene of SARS-CoV-2 (NC_045512.2) was incorporated into 921 the pSecTag2/Hygro A plasmid and used as a template to generate S mutants by site- 

The authors declare no competing interests. 1014 1015 1016